altimmune glp-1 stock sinks on mixed phase 2 MASH results for drug 🚨 ALTIMMUNE (ALT) — THE

doi: 10.1038/s41598-023-49610-3 205 GarnierLAlbanoJP

First-time prescribing of ADMs decreased in September 2025, relative to June 2025 (-16.8%)

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an n-terminally truncated peptide that is a major endogenous metabolite in vivo

Limitations and perspectives Therapeutic approaches targeting cardiac remodeling reversal, including monoclonal antibodies, peptide-based therapies, and AAV vectors, share similar translational challenges with cardiac regeneration strategies, particularly with respect to delivery efficiency and potential off-target effects